R acial disparities in cardiac care have been widely reported, including lower use of evidence-based medications and revascularization procedures after myocardial infarction (MI) 1-5 among minority populations. These disparities are exacerbated by lower rates of treatment in patients of older age. [6] [7] [8] To date, studies have found that these differences in care processes do not appear to adversely affect short-term (in-hospital) outcomes. Nevertheless, there has been limited study of whether longitudinal survival and readmission risk are adversely affected by differential cardiac care.
Heart Association (ACC/AHA) Guidelines? (CRUSADE) registry data to Centers for Medicare & Medicaid Services (CMS) administrative data to compare long-term outcomes between older blacks and whites in a nationwide sample of MI patients. Our objectives were to compare both short-and long-term outcomes of all-cause death and readmission (for all-cause, acute MI, and heart failure [HF]) of non-ST-segment-elevation MI patients according to race. Furthermore, we sought to evaluate whether differences in outcomes persisted after adjustment for patient baseline characteristics and treatment differences.
Methods

Data Sources
The CRUSADE registry was a voluntary observational data collection and quality-improvement initiative that collected prospective data on patients with non-ST-segment elevation acute coronary syndrome from January 2001 to December 2006. CRUSADE was designed to track guideline adherence, to provide feedback about performance, and to develop quality improvement tools to improve adherence to ACC/AHA recommendations for the treatment of acute coronary syndrome patients. 9 Inclusion and exclusion criteria, data collection, and variables have previously been described. 9 The individual institutional review board of each reporting hospital approved participation in CRUSADE. All data were abstracted retrospectively and anonymously; therefore, informed consent was not required.
The process of linking clinical registry data to CMS administrative data has been described previously. 10 Briefly, we used indirect identifiers (ie, site, age, admission and discharge dates, and sex) to link CRUSADE registry patients to a unique record in the CMS administrative database.
From the original sample of 101 464 patients with non-ST-segment elevation MI who were ≥65 years old and were included in CRUSADE from 2001 to 2006, 73 660 patients (73%) with non-ST-segment-elevation MI from 514 US hospitals were matched to CMS longitudinal administrative data through the end of 2008.
Study Population
We limited our population to the CRUSADE enrollment period between February 15, 2003, and December 31, 2006 , because of the availability of more complete data during that time, yielding a study population of 45 860 patients. From this sample, we sequentially excluded patients who were neither black nor white (n=3043), patients who did not match on sex (n=501), patients who died but were listed as being discharged on a later date in CMS data (n=28), and nonindex admissions (ie, patients from the originally linked sample who had repeat admissions in the CRUSADE registry and only their index admission was analyzed; n=1788). The final mortality analysis population consisted of 40 500 patients from 446 sites participating in CRUSADE. For the readmission analyses, an additional 3 exclusion criteria were applied (sequentially): patients who died during the index admission (n=2522), patients who were not eligible for Medicare Part A and B fee-for-service plans during the index admission (n=1781), and patients with an invalid time to readmission (n=7), yielding a final population of 36 190 patients across 446 CRUSADE sites.
Study Variables and Definitions
Participating hospitals used a standardized set of data elements and definitions to collect detailed information on baseline demographic and clinical characteristics, processes of care, and in-hospital outcomes. Data were screened on entry, and only those data that met predetermined criteria for completeness and accuracy were entered into the database. Acute care and discharge treatments were defined as the use of medications within the first 24 hours of index admission and those on medications discharged from the index hospitalization, respectively. All other variables have previously been described. 9 Because cause-specific mortality was not available from the CRUSADE and CMS databases, the outcome of interest in our study was all-cause mortality. Furthermore, we studied all-cause readmission, acute MI readmission, and HF readmission. International Classification of Diseases, Ninth Revision primary discharge diagnosis code 410.x was used to classify acute MI readmission, and codes 428.x, 402.x1, 404.x1, 404.x3, and 398.91 were used to classify HF readmission. Transfers to or from another hospital and admission for rehabilitation were not considered readmissions.
Statistical Analysis
Patient baseline characteristics and in-hospital treatment patterns and outcomes were compared between black and white patients by use of the Mantel-Haenszel χ 2 test for categorical variables and the Wilcoxon rank-sum test for continuous variables. Frequencies and percentages were used for categorical variables, and medians (with 25th and 75th percentiles) were used for continuous variables.
The primary outcomes of interest were time to first event for allcause mortality and readmission (for all-cause, acute MI, and HF). Kaplan-Meier curves were generated to estimate the probability of mortality by race, and the log-rank test was used to assess whether the differences between the mortality curves were statistically significant at P<0.05. The incidence of all-cause, acute MI, and HF readmission is directly influenced by the competing risk for mortality; therefore, we estimated the cumulative incidence of readmission at various time points after the index admission. 11 The incidence for all-cause, acute MI, and HF readmission was compared between black and white patients by use of the Gray test.
Cox proportional hazards modeling was performed to examine the association between race and short-and long-term outcomes. Robust standard errors were used to account for clustering of patients within hospitals. 12 Because historical data on survival of black versus white patients have shown different short-and long-term mortality according to race, [13] [14] [15] separate analyses were performed in each time period. The follow-up period for short-term mortality was 30 days from the date of index admission (n=40 500). Short-term readmission was assessed among those who survived the initial hospitalization and those eligible for Medicare Part A and B fee-for-service plans during the index admission, with follow-up from discharge to 30 days afterward (n=36 190).
Analysis of long-term mortality included only those patients who survived the initial hospitalization and the first 30 days after discharge (n=36 046) and continued for a mean of 2.6 years. Long-term readmission was evaluated starting 30 days after discharge and included only survivors who had not been readmitted within the first 30 days (n=27 618). Maximum follow-up was 4 years, and subjects were censored beyond this point.
The models were adjusted sequentially to see the contribution of different types of covariates. The primary mortality analysis was adjusted for variables based on the CRUSADE mortality model 16 : age, weight, sex, prior stroke, diabetes mellitus, peripheral artery disease, hypertension, dyslipidemia, prior percutaneous coronary intervention, prior MI, prior coronary bypass grafting, current or recent smoker, history of HF, signs of HF, family history of coronary artery disease, systolic blood pressure and heart rate on admission, initial serum creatinine, initial hematocrit, initial troponin ratio, and electrocardiogram (ECG) findings (model 1).
For the primary readmission analyses, acute episodes of care within the past year and hospital transfer-in status were additionally included in the list of covariates; we referred to this model as model 1 for all readmission analyses. Including the covariates in model 1, we then sequentially adjusted for insurance coverage beyond Medicare (model 2), income level (income level was determined from the 2006 area resource file 17 merged with the facility ZIP code; high and low incomes were determined from median income; model 3), discharge medications (aspirin, β-blocker, any lipid-lowering agent, angiotensin-converting enzyme inhibitor, and clopidogrel; model 4), and revascularization through percutaneous coronary intervention or coronary bypass grafting (model 5). We also investigated the impact of hospital region (Northeast, Midwest, West, and South) and academic versus nonacademic (defined as membership in the Council of Teaching Hospitals). Finally, we evaluated whether the impact of specific prognostic subgroups-sex, age group (≥75 and <75 years of age), diabetes mellitus, and income level-varied by race by testing by guest on July 26, 2017 http://circ.ahajournals.org/ Downloaded from for interaction between race and subgroups. For statistically significant interactions, the hazard ratios (HRs) with 95% confidence intervals (CIs) for outcomes by race were reported among subgroups.
To assess the differential impact between large MIs caused by acute plaque rupture and smaller MIs resulting from complications of hypertension, renal failure, and other comorbidities, we performed sensitivity analyses restricted to patients having large MIs as defined by peak troponin values <5-fold the upper limit of normal (n=27 196).
All analyses were performed with the SAS software package (SAS 9.3; SAS Institute, Cary, NC).
Results
Baseline Clinical Characteristics
In our final population, 7.7% of patients (n=3116) were black and 92.3% (n=37 384) were white. Although all patients were >65 years of age, black patients were younger than white patients (median age, 76 versus 78 years) but had a higher prevalence of prior HF, stroke, diabetes mellitus, and hypertension and a much higher prevalence of both renal insufficiency and ongoing dialysis ( Table 1) . Blacks more often had HF on presentation but less often exhibited dynamic ST changes on an ECG. Compared with white patients, black patients less often had additional private insurance coverage.
Patterns of Treatment
Black patients were less often treated with short-term antiplatelet therapies such as glycoprotein IIb/IIIa inhibitors (34.0% versus 41.0%) and clopidogrel (45.0% versus 52.5%), whereas rates of aspirin, heparin, or β-blocker use were not significantly different between the groups (Table 2) . Black patients less often underwent diagnostic cardiac catheterization and revascularization through percutaneous coronary intervention or coronary bypass grafting. At discharge, black patients less often received clopidogrel compared with white patients, but there was no difference in the receipt of aspirin, β-blockers, and lipid-lowering agents.
Outcomes
Mortality At 30 days after MI, black patients had a similar unadjusted mortality rate relative to white patients (9.1% versus 9.9%; P=0. 13 ), yet by 6 months, these curves crossed (20.1% versus 18.9%; P=0.17), and by 1 year, mortality was higher among blacks than whites and remained parallel thereafter: 1 year, 27.9% versus 24.5% (P<0.001); 2 years, 37.7% versus 33.3% (P<0.001); and 3 years, 44.6% versus 40.5% (P<0.001; Figure 1 ). After adjustment for patient baseline clinical risk factors, the difference in 30-day mortality widened in favor of black patients (HR, 0.80; 95% CI, 0.71-0.92; model 1; Figure 2 ). In contrast, beyond 30 days, long-term adjusted mortality was not significantly different between groups (HR, 1.00; 95% CI, 0.94-1.07; model 1), and similar results were found with models adjusting for additional variables of other insurance coverage beyond Medicare, income level, discharge medications, and in-hospital revascularization (Figure 2 ). When hospital characteristics were included in the last model, we also noted no additional impact of hospital region or teaching hospital on short-or long-term mortality (data not presented). Furthermore, the effect of prognostic factors such as sex, age, diabetes mellitus, and income was similar according to race for short-term mortality (P interaction >0.05; Table I in the online-only Data Supplement).
Readmission
Observed cumulative incidence rates of all-cause readmission were higher among black patients compared with white patients at 30 days (23.6% versus 20.0%; P<0.001), 6 months (50.5% versus 43.2%; P<0.001), 1 year (62.0% versus 54.6%; P<0.001), 2 years (73.1% versus 66.7%; P<0.001), and 3 years (78.9% versus 73.5%; P<0.001; Figure 3A ). Nevertheless, after adjustment for patient case-mix and treatment strategies, there was no significant difference in shortand long-term all-cause readmission between black and white patients (Figure 4 ). We also found no difference in readmission after adjustment for hospital region and teaching hospital status (data not presented). Finally, the interaction between subgroups (according to sex, age group, diabetes mellitus, and income level) and race was not statistically significant for short-and long-term all-cause readmission ( Table II in the online-only Data Supplement).
We also evaluated cause-specific readmission resulting from acute MI or HF. As seen in the cumulative incidence curves, black patients had an increased incidence of acute Figure 3B and 3C ). After adjustment, there was no difference in short-and long-term readmission for acute MI between the race groups, but black patients remained more likely to be readmitted long term with HF (HR, 1.13; 95% CI, 1.03-1.24; model 1; Figure 4 ). After adjustment for patient case mix (model 1), the interaction between sex and race for short-term readmission for HF was significant (men: HR, 1.38; 95% CI, 1.10-1.74; women: HR, 0.83; 95% CI, 0.65--1.06; Table II in the online-only Data Supplement).
Sensitivity Analysis
To assess the effect of MI size on clinical outcomes, we performed sensitivity analyses limiting our population to those patients with peak troponin values >5 times the upper limit of normal. The results of sensitivity analyses were similar to the results of the main analysis: Black patients continued to have lower 30-day adjusted mortality (HR, 0.80; 95% CI, 0.68-0.94; model 1) but similar adjusted long-term mortality compared with white patients (HR, 0.98; 95% CI, 0.90-1.07; model 1; Table I in the online-only Data Supplement). The increased risk of 30-day and long-term all-cause readmission that blacks maintained over whites was again attenuated after adjustment for patient case mix (HR, 1.08; 95% CI, 0.96-1.21; and HR, 1.03; 95% CI, 0.95-1.11, respectively; model 1; Table II in the online-only Data Supplement). Although black patients remained more likely to be readmitted for HF over long-term follow-up in our main analysis, this no longer reached statistical significance among patients with peak troponin >5 times the upper limit of normal (HR, 1.13; 95% CI, 0.98-1.30; model 1).
Discussion
Despite receiving fewer guideline-based acute medical treatments and coronary revascularization, blacks had lower 30-day mortality than whites after adjustment for patient baseline differences; however, among survivors to 30 days, this early advantage of blacks was lost over the long term. Additionally, black patients were more often readmitted for HF than white patients in long-term follow-up.
Differences in Care
As in previous reports, we note similar use of most secondary prevention medications but found poorer uptake of newer and more potent antiplatelet therapies 5 and less use of invasive procedures among blacks in the treatment of MI. 18 The reasons for this are multifactorial and likely include a physician's decision to avoid more aggressive treatments because of patient comorbidities. Invasive procedures carry upfront risks that are increased among certain subgroups. These risks may lead to renal failure after contrast dye injection or increased morbidity among those who undergo coronary bypass grafting 19 ; however, the lack of an invasive evaluation may deprive these higher-risk patients of the long-term benefits from revascularization such as improved downstream morbidity or mortality. 7 Other factors that have been cited include lack of financial resources and possible provider bias. 20 Additionally, it is possible that age and culture-related issues such as patient-provider communication, 21 patient selfhealth awareness, 22 and overall social support structures 23 may contribute to disparities in receipt of diagnostic and therapeutic treatments.
Short-Term Mortality
We noted significantly lower adjusted 30-day mortality in blacks than in whites despite differential treatments with fewer guideline-based therapies. Several prior analyses have found similar results of a short-term survival advantage among blacks compared with whites for cardiac and noncardiac conditions. [13] [14] [15] 24, 25 One possibility for these findings in black patients may be the higher prevalence of type 2 or secondary MIs seen in the setting of renal failure or hypertensive disease. These MIs are caused by increased oxygen demand or decreased oxygen supply rather than acute plaque rupture 26 and are often associated with smaller infarct size and less myocardial damage as evidenced by lower troponin elevations. These secondary MIs may have less of a detrimental effect on clinical outcomes than larger MIs. Nevertheless, our sensitivity analyses did not support this hypothesis; rather, we found that blacks still had lower 30-day adjusted mortality even with smaller MIs excluded. Alternatively, the racial †Long term among survivors who had not been readmitted within the first 30 days after discharge; data are displayed as hazard ratio (95% confidence interval).
by guest on July 26, 2017 http://circ.ahajournals.org/ Downloaded from differences in short-term survival may also reflect a "survivor effect" in which blacks who survive to age 65 may represent a healthier cohort of patients than white patients of the same age. [13] [14] [15] It is also unknown whether black patients with larger MIs may be more likely to die before reaching the hospital; therefore, those blacks who are admitted may have less severe disease than whites. In addition to age and sex, there are likely additional unmeasured differences between these groups that confer a protective benefit toward black patients that we have not fully captured or adjusted for.
Long-Term Mortality
The early survival advantage noted at 30 days in which blacks had lower adjusted mortality than whites is not sustained over the long term when risk-adjusted mortality among blacks was similar to whites. We found no incremental difference in the magnitude of the HR in long-term mortality among the groups after additional adjustment for socioeconomic status, discharge medications, and in-hospital revascularization.
Our results support previous findings that black patients are less likely to be referred for coronary angiography and are less likely to undergo percutaneous or surgical revascularization after an acute MI, even when accounting for comorbid illnesses and disease severity. 1, 5, 7, 8, 24, [27] [28] [29] [30] Although this did not affect their short-term mortality in which they had a survival advantage, it is clear that blacks did not maintain that same trajectory of survival over whites. This convergence of longterm survival may be due to a combination of less revascularization and accelerated progression of complications from their comorbidities and postdischarge influences that were not adequately captured in this analysis. Although we did not find that differential rates of revascularization modified the relative risk for death among blacks over time, it is possible that the receipt of revascularization itself may instead be a marker for better follow-up or long-term care such as more aggressive management of comorbidities and cardiac risk factors.
Readmissions
Previous studies have found that black race may be an independent predictor of 30-day readmission among Medicare beneficiaries. 31 Despite the fact that we found consistently higher crude rates of all-cause and HF readmission within 30 days in blacks than in whites, these differences diminished after adjustment. Similarly, in examinations of long-term follow-up, blacks continued to have higher unadjusted cumulative incidence rates of all-cause and acute MI readmission that again were attenuated after adjustment. This attenuation of readmission risk with adjustment of patient characteristics reflects the increased burden of comorbid disease in blacks compared with whites at the time of their event. Interestingly, even after adjustment, blacks remained more likely to be readmitted for HF over long-term follow-up. In addition to differences in chronic conditions between blacks and whites, it is possible that reasons other than the covariates included in this multivariate model contribute to the likelihood of readmission. For example, poor medication adherence after discharge, limited access to follow-up care, or poor-quality outpatient managemen [32] [33] [34] may also be implicated in readmission.
Clearly, the early survival advantage of black patients erodes as time from the index admission passes, implicating unmeasured factors once these patients return home. Recent attention on readmissions deemed preventable has placed focus on care that occurs after discharge such as availability of social support, quality of ambulatory care, and adherence to prescribed medications. All of these postdischarge factors may influence long-term outcomes and may, in part, explain some of the differential long-term findings in our study. Therefore, moving forward, quality improvement efforts should be multifaceted 
Limitations
Our study should be considered in light of several limitations. First, our long-term analysis of mortality and readmission outcomes is limited to an elderly population enrolled in fee-for-service Medicare; as a result, our analysis may not be generalizable to younger patients or those with alternative primary insurance coverage. Second, despite the fact that the association between race, care rendered, and outcomes was adjusted for patient case mix, unmeasured confounding or bias in this observational data set is possible. For example, the effect of race on cardiovascular outcomes is often intertwined with measures of socioeconomic status, including insurance coverage, income and educational level, and access to health care. Despite the fact that we attempted to control for some of these factors through the use of aggregate census data, the methodology is imperfect. In addition, the use of revascularization during the index admission is not randomized and is influenced by differences in baseline comorbidities between the race groups and by differences in coronary anatomy that are not collected in our data set. Third, we do not have data on postdischarge factors that may influence downstream outcomes such as adherence to medications prescribed or physician follow-up after discharge. Finally, hospitals participate in CRUSADE voluntarily, and urban centers that treat a larger proportion of black and minority patients may not be well represented in this group.
Conclusions
Despite efforts aimed at mitigating racial disparities in the use of evidence-based treatments and adverse clinical outcomes among patients with acute MI, our study found persistent differences, even among older patients. In addition to a higher burden of chronic illness among blacks, differences in MI care and postdischarge management may contribute to the discrepancies in short-and long-term outcomes among blacks and whites. The factors underlying racial disparities are complex and may reflect differences ranging from clinical presentation and medical decision making to environmental barriers limiting access to quality health care once patients have transitioned back into the community. Further work is needed to understand and prevent the erosion of benefit in long-term outcomes in blacks. 
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